

Protein-Energy Malnutrition in Patients with Liver Cirrhosis

Katsuhisa OMAGARI^{1,2}, Manami KAJI¹, Yuka ISHII¹, Haruka IWAMI¹, Mayuko ICHIMURA², Sachiko MATSUTAKE², Shigeiko KATO^{1,2}, Shigeyuki TAKESHITA³, Tatsuki ICHIKAWA³, Kazuhiko NAKAO³

¹Department of Nutrition, Faculty of Nursing and Nutrition, University of Nagasaki, Siebold, Nagasaki, Japan

²Division of Nutritional Sciences, Graduate School of Human Health Science, University of Nagasaki, Siebold, Nagasaki, Japan

³Department of Gastroenterology and Hepatology, Graduate School of Biomedical Science, Nagasaki University, Nagasaki, Japan

Protein-energy malnutrition (PEM) is frequently seen in patients with liver cirrhosis. This condition is associated with a poor prognosis and reduced survival. We investigated the protein and energy metabolic status, including serum albumin concentration, and resting energy expenditure (REE) and respiratory quotient (RQ) measured by indirect calorimetry in 23 patients with liver cirrhosis (8 men and 15 women; mean age, 60.3 years). The median value of %REE (measured REE / predicted REE) was highest in Child-Pugh grade A and lowest in grade C, and the range of RQ tended to be highest in Child-Pugh grade A and lowest in grade C, although there were not statistically significant ($p=0.871$ and 0.664 , respectively). Serum triglyceride concentration was significantly lower in patients who had an RQ less than 0.85 than in patients who had an RQ of 0.85 or more, and free fatty acid tended to be higher in patients who had an RQ less than 0.85 than in patients who had an RQ of 0.85 or more. Of the 23 patients, 78.3% were in a state of protein and/or energy malnutrition and 47.8% had PEM. Our results suggest that %REE and RQ were not significantly associated with liver function, but the oxidation rate of fat was increased in advanced liver cirrhosis. A longitudinal study in a large population is needed to determine the efficacy of %REE and RQ measurements for adequate nutritional treatment and improvement of patient outcome.

ACTA MEDICA NAGASAKIENSIA 57: 5 - 12, 2012

Keywords: Respiratory quotient, Indirect calorimetry, Liver cirrhosis, Protein-energy malnutrition

Introduction

Protein-energy malnutrition (PEM) is a common clinical manifestation of patients with liver cirrhosis.¹⁻⁷ Lautz et al.⁸ reported that 65% of patients with liver cirrhosis showed some signs of PEM as indicated by low body cell mass, reduced serum albumin concentrations, or abnormal skinfold thickness. This is mainly due to abnormal fuel metabolism including visceral and skeletal muscle protein-catabolic state,⁹ increased fat oxidation, and decreased glucose oxidation.¹⁰ This condition is associated with a poor prognosis and reduced survival.^{9,11} Therefore, accurate assessments of nutritional status such as measurement of energy expenditure

may be of clinical value in cases of liver cirrhosis.^{12,13}

Indirect calorimetry is an established method for estimating energy malnutrition, despite being expensive and requiring training to use. Resting energy expenditure (REE) and respiratory quotient (RQ) are the main parameters considered when evaluating energy metabolism by indirect calorimetry.¹¹ RQ has been reported to decrease after an overnight fast in cirrhotic patients in many studies, but whether increased basal or resting energy expenditure is a constant feature in liver cirrhosis remains controversial.^{1,3}

In the present study, we aimed to investigate the protein and energy metabolic statuses, including the measurement of serum albumin concentration, and the measurement of

Address correspondence: Katsuhisa Omagari, M.D., Department of Nutrition, Faculty of Nursing and Nutrition, University of Nagasaki, Siebold, 1-1-1 Manabino, Nagayo-cho, Nagasaki 851-2195, Japan

TEL & FAX: +81-95-813-5201, E-mail: omagari@sun.ac.jp

Received October 6, 2011; Accepted December 21, 2011

REE and RQ by indirect calorimetry, in patients with liver cirrhosis.

Patients and Methods

Patients

Of the 150 patients who were admitted to the Department of Gastroenterology and Hepatology, Nagasaki University Hospital, Japan, and who also underwent indirect calorimetry between April 2008 and October 2009, 23 patients with liver cirrhosis (8 men and 15 women; mean age, 60.3 ± 10.3 years) were included in the present study. The medical records of the 23 patients with liver cirrhosis were collected and analyzed. The collected data included sex, age, etiology of liver cirrhosis, Child-Pugh grade (Table 1),^{14,15} height, body weight, history of alcohol intake, associated disease such as hypertension, diabetes mellitus, and esophageal varices, and history of branched-chain amino acid (BCAA) treatment. The laboratory data such as peripheral platelet count (PLT), C-reactive protein (CRP), serum levels of albumin (ALB), total bilirubin (TB), aspartate aminotransferase (AST), alanine aminotransferase (ALT), total cholesterol (TC), triglyceride (TG), free fatty acid (FFA), blood urea nitrogen (BUN), creatinine (Cr), sodium (Na), potassium (K), chloride (Cl), calcium (Ca), and phosphorus (P), fasting blood glucose (FBG), immunoreactive insulin (IRI), prothrombin time (PT), ammonia (NH₃), and BCAA to tyrosine ratio (BTR) were also collected. Standard biochemical tests were performed on a multichannel autoanalyzer.

The history of alcohol intake was divided into two groups as follows: drinker (at least 70 g/day of alcohol intake for more than 5 years) and non- or light-drinker (less than 70 g/day of alcohol intake for up to 5 years). The diagnosis of

liver cirrhosis was based on a compatible clinical history, radiological studies, and/or histopathological examination when available. Patients who were seropositive for hepatitis B surface antigen (HBsAg) were classified as "hepatitis B virus (HBV)-related"; those who were seropositive for antibody to hepatitis C virus (anti-HCV) as "HCV-related"; those who were drinkers and seronegative for HBsAg and anti-HCV as "alcoholic"; and those who were non- or light-drinkers and seronegative for HBsAg and anti-HCV as "others". The body mass index (BMI) was calculated as body weight (kg) divided by height squared (m²).

Indirect calorimetry

Indirect calorimetry was carried out in the morning after overnight bed rest and fasting using a Vmax SPECTRA 29n calorimeter (Cardinal Health 207. Inc., Dublin, OH, USA). The equipment was calibrated at the start of each measurement in accordance with the manufacturer's instructions. About 3 or 4 minutes after the patient rested in the supine position in a rigid canopy (placed over the head in which the patient respires freely), oxygen consumption per minute (VO₂) and carbon dioxide production per minute (VCO₂) were measured during a period of at least 15 minutes. Resting energy expenditure (REE) was calculated using the modified Weir formula¹⁶ as follows: REE (kcal/day) = [3.9 x VO₂ (L/min) + 1.1 x VCO₂ (L/min)] x 1440. Respiratory quotient (RQ) was calculated as follows: RQ = VCO₂ (L/min) / VO₂ (L/min). The predicted REE was estimated from the Harris-Benedict equations¹⁷ as follows: basal metabolic rate (BMR) (kcal/day) for men = 66.47 + 13.75 x body weight (kg) + 5.00 x height (cm) - 6.75 x age (years). The BMR (kcal/day) for women = 655.10 + 9.56 x body weight (kg) + 1.85 x height (cm) - 4.68 x age (years). The %REE was calculated as follows: %REE = measured REE (kcal/day) / predicted REE (kcal/day).

Table 1. Definition and criteria of Child-Pugh classification

Clinical and laboratory findings	Score		
	1 point	2 points	3 points
Encephalopathy occasionally	None	Mild	Coma
Ascites	Absent	Slight	Moderate
Serum TB (mg/dL)	<2.0	2.0-3.0	>3.0
Serum ALB (g/dL)	>3.5	2.8-3.5	<2.8
PT (%)	>70	40-70	<40

Definition and criteria of encephalopathy and prothrombin time are modified according to the Liver Cancer Study Group of Japan.^{14,15} The scores for all findings are totaled, and a final score of 5-6 is assigned a Child-Pugh grade A, score of 7-9 is grade B, and score of 10-15 is grade C. Refer to the text in the Patients and Methods section for abbreviations.

Ethical consideration

This study was performed according to the principles of the Declaration of Helsinki. The study protocol was approved by the Ethical Committee of University of Nagasaki. Informed consent was obtained from all participants in Nagasaki University Hospital.

Statistical analysis

Data were expressed as mean \pm standard deviation (SD) or as median (range). Differences between groups were

tested for statistical significance using the two-tailed Mann-Whitney U-test, Kruskal-Wallis test followed by Bonferroni's multiple comparison test, chi-square test, or Fisher's exact probability test. All data analyses were performed using IBM SPSS statistics software, version 17.0 (IBM Co., Somers, NY) on a computer with a Windows operating system. A *p*-value less than 0.05 was considered statistically significant.

Results

Clinical characteristics of 23 patients with liver cirrhosis

The clinical features of 23 patients with liver cirrhosis are shown in Table 2. The etiology of liver cirrhosis was "HBV-related" in 5 patients, "HCV-related" in 9 patients, "alcoholic" in 4 patients, and "others" in 5 patients. Of the 5 patients who were categorized as "others", 3 were diagnosed as primary biliary cirrhosis (PBC), one as autoimmune hepatitis (AIH), and one as PBC-AIH overlapping syn-

Table 2. Clinical characteristics of 23 patients with liver cirrhosis

Feature	Number examined	Result
Men/women	23	8/15
Age (years)	23	64 (34-76)
Etiology* (HBV/HCV/alcohol/others)	23	5/9/4/5
Child-Pugh grade (A/B/C)	23	8/7/8
Height (m)	23	1.53 (1.42-1.75)
Body weight (kg)	23	56.4 (37.0-90.0)
BMI (kg/m ²)	23	24.0 (16.4-29.7)
REE (kcal/day)	23	1163 (956-1667)
%REE	23	100 (81-126)
RQ	23	0.83 (0.72-1.02)
VO ₂ (L/min)	23	0.17 (0.13-0.24)
VCO ₂ (L/min)	23	0.14 (0.12-0.20)
PLT (x10 ³ /mm ³)	23	12.5 (3.1-35.0)
CRP (mg/dL)	22	0.25 (0.02-1.15)
ALB (g/dL)	23	3.1 (2.3-4.3)
TB (mg/dL)	23	1.4 (0.4-26.7)
AST (IU/L)	23	42 (14-156)
ALT (IU/L)	23	29 (8-73)
FBG (mg/dL)	16	104 (62-166)
IRI (μU/mL)	11	8.8 (3.5-107.3)
TC (mg/dL)	14	134 (87-377)
TG (mg/dL)	16	84 (23-314)
FFA (mEq/L)	13	0.73 (0.25-1.57)
BUN (mg/dL)	23	17 (4-66)
Cr (mg/dL)	23	0.72 (0.42-2.09)
Na (mEq/L)	23	137 (125-143)
K (mEq/L)	23	4.0 (3.3-4.9)
Cl (mEq/L)	23	104 (91-108)
Ca (mg/dL)	13	8.7 (8.2-9.8)
P (mg/dL)	10	3.3 (1.9-4.6)
PT (%)	23	64 (32-120)
NH ₃ (μg/dL)	18	77 (34-174)
BTR	16	3.06 (1.32-8.85)
History of alcohol intake (non- or light-drinker/drinker/unknown)	23	15/5/3
Diabetes mellitus (absent/present)	23	12/11
Hypertension (absent/present)	23	16/7
Esophageal varices (absent/present)	23	12/11
BCAA treatment (absent/present)	23	13/10

*HBV, hepatitis B virus-related; HCV, hepatitis C virus-related.

Refer to the text in the Patients and Methods section for other abbreviations.

Age, height, body weight, body mass index, metabolic parameters, peripheral platelet count, and blood biochemical parameters are expressed as median (range).

drome. Mild hepatic encephalopathy occurred in only one patient. Minimum ascites was observed in 2 patients and moderate ascites was detected in 10 patients. Serum TB was 2.0-3.0 mg/dL in one patient and more than 3.0 mg/dL in 6 patients. Serum ALB was 2.8-3.5 g/dL in 9 patients and less than 2.8 g/dL in 6 patients. Prothrombin time was 40%-70% in 14 patients and less than 40% in 2 patients. The aggregate Child-Pugh score ranged from 5 to 13 points and the median value was 8. Overall, 8 patients were categorized as Child-Pugh grade A, 7 patients as grade B, and 8 patients as grade C.

Comparison of clinical features among patients who were categorized as Child-Pugh grade A, B, and C

Except for the laboratory findings included in Child-Pugh classification such as serum TB, ALB, and PT, there were significant differences in serum Na, Ca, TC, and frequency of receiving BCAA treatment among patients who were categorized as Child-Pugh grade A, B, and C. Particularly, BCAA treatment was more common in patients categorized as Child-Pugh grade C (Table 3). There were no significant differences in %REE and RQ among patients who were

Table 3. Comparison of clinical features among patients who are categorized as Child-Pugh grade A, B, and C

Feature	Grade A	Grade B	Grade C	P
Men/women	3/5	3/4	2/6	0.866
Age (years)	65 (46-76)	65 (49-72)	51 (34-65)	0.095
Etiology (HBV/HCV/alcohol/others)	2/3/1/2	1/4/1/1	2/2/2/2	0.971
Height (m)	1.52 (1.42-1.64)	1.55 (1.43-1.67)	1.52 (1.45-1.75)	0.675
Body weight (kg)	56.1 (47.2-63.5)	59.0 (43.5-68.5)	56.7 (37.0-90.0)	0.777
BMI (kg/m ²)	23.2 (20.7-29.4)	24.0 (18.1-29.7)	26.0 (16.4-29.4)	0.838
REE (kcal/day)	1164 (956-1300)	1138 (1021-1667)	1180 (1100-1578)	0.450
%REE	103 (90-110)	101 (81-118)	97 (81-126)	0.871
RQ	0.83 (0.78-1.02)	0.84 (0.76-0.87)	0.82 (0.72-0.92)	0.664
VO ₂ (L/min)	0.17 (0.13-0.19)	0.16 (0.15-0.24)	0.17 (0.15-0.23)	0.474
VCO ₂ (L/min)	0.14 (0.13-0.17)	0.13 (0.12-0.20)	0.14 (0.12-0.18)	0.646
PLT (x10 ³ /mm ³)	15.3 (6.4-31.2)	13.6 (6.6-35.0)	9.1 (3.1-17.6)	0.204
CRP (mg/dL)	0.15 (0.02-1.15)	0.23 (0.05-0.25)	0.43 (0.17-0.73)	0.227
ALB (g/dL)	3.7 (2.9-4.3)	3.1 (2.7-3.6)	2.8 (2.3-3.2)	0.003
TB (mg/dL)	0.9 (0.4-1.4)	0.9 (0.5-1.4)	3.9 (1.5-26.7)	0.001
AST (IU/L)	39 (14-74)	43 (18-63)	53 (23-156)	0.342
ALT (IU/L)	30 (10-53)	32 (8-39)	28 (13-73)	0.742
FBG (mg/dL)	111 (62-133)	93.5 (79-166)	118 (72-144)	0.934
IRI (μU/mL)	13.3 (4.2-15.0)	6.7 (3.5-107.3)	16.6 (8.6-24.6)	0.736
TC (mg/dL)	177 (102-377)	114 (105-174)	95 (87-102)	0.039
TG (mg/dL)	81 (63-314)	84 (48-117)	114 (23-125)	0.972
FFA (mEq/L)	0.75 (0.29-1.57)	0.55 (0.25-1.03)	0.86 (0.61-1.54)	0.453
BUN (mg/dL)	17 (4-23)	16 (10-66)	17 (5-48)	0.856
Cr (mg/dL)	0.74 (0.42-1.28)	0.85 (0.56-1.97)	0.62 (0.43-2.09)	0.519
Na (mEq/L)	138 (136-140)	138 (132-139)	132 (125-143)	0.031
K (mEq/L)	4.3 (3.3-4.7)	3.9 (3.3-4.9)	3.9 (3.5-4.9)	0.606
Cl (mEq/L)	104 (99-107)	105 (98-108)	100 (91-106)	0.061
Ca (mg/dL)	9.3 (8.9-9.8)	8.4 (8.2-8.7)	8.6 (8.5-9.2)	0.015
P (mg/dL)	4.3 (3.4-4.6)	3.3 (2.6-3.5)	2.7 (1.9-3.0)	0.060
PT (%)	84 (57-120)	64 (45-70)	46 (32-67)	0.002
NH ₃ (μg/dL)	71 (60-105)	115 (62-174)	83 (34-145)	0.411
BTR	3.44 (2.86-7.26)	3.11 (2.73-4.64)	2.75 (1.32-8.85)	0.452
History of alcohol intake (non- or light-drinker/drinker/unknown)	5/1/2	6/0/1	4/4/0	0.123
Diabetes mellitus (absent/present)	3/5	5/2	4/4	0.508
Hypertension (absent/present)	4/4	4/3	8/0	0.073
Esophageal varices (absent/present)	4/4	4/3	4/4	1.000
BCAA treatment (absent/present)	8/0	4/3	1/7	0.001

Refer to the text in the Patients and Methods section and Table 2 for abbreviations.

Age, height, body weight, body mass index, metabolic parameters, peripheral platelet count, and blood biochemical parameters are expressed as median (range)

categorized as Child-Pugh grade A, B, and C, but the median value of %REE was highest in Child-Pugh grade A and lowest in grade C. Moreover, the range of RQ tended to be highest in Child-Pugh grade A and lowest in grade C, although there were not statistically significant (Fig. 1).

Comparison of clinical features between patients who had a respiratory quotient less than 0.85 and patients who had a respiratory quotient of 0.85 or more

Because an RQ of 0.85 was reported to be the point at

which substrate for thermogenesis turned from carbohydrate dominant (RQ>0.85) to fat dominant (RQ<0.85), and survival rate was significantly lower in patients with low RQ (<0.85) than in patients with scores above 0.85,³ we conducted a comparison of clinical features between patients who had an RQ less than 0.85 and patients who had RQ of 0.85 or more (Table 4). Height was significantly higher in patients who had an RQ less than 0.85 than in patients who had an RQ of 0.85 or more. Serum TG was significantly lower in patients who had an RQ less than 0.85 than in patients who had an RQ of 0.85 or more, and FFA

Table 4. Comparison of clinical features between patients who have a respiratory quotient less than 0.85 and patients who have a respiratory quotient of 0.85 or more

Feature	RQ<0.85	RQ≥0.85	P
Men/women	7/7	1/8	0.086
Age (years)	62.5 (34-76)	64 (46-72)	0.728
Etiology (HBV/HCV/alcohol/others)	4/7/3/0	1/2/1/5	0.009
Child-Pugh grade (A/B/C)	5/4/5	3/3/3	0.484
Height (m)	1.55 (1.45-1.75)	1.46 (1.42-1.67)	0.012
Body weight (kg)	56.1 (43.5-90.0)	59.0 (37.0-68.5)	0.753
BMI (kg/m ²)	22.2 (18.1-29.4)	25.7 (16.4-29.7)	0.176
REE (kcal/day)	1163 (1021-1667)	1179 (956-1402)	0.614
%REE	101 (81-126)	98 (90-111)	0.592
VO ₂ (L/min)	0.17 (0.15-0.24)	0.17 (0.13-0.20)	0.256
VCO ₂ (L/min)	0.14 (0.12-0.20)	0.14 (0.13-0.17)	0.313
PLT (x10 ³ /mm ³)	12.2 (3.1-35.0)	13.0 (6.4-31.2)	0.925
CRP (mg/dL)	0.42 (0.08-0.73)	0.23 (0.02-1.15)	0.306
ALB (g/dL)	3.0 (2.4-4.2)	3.5 (2.3-4.3)	0.218
TB (mg/dL)	1.3 (0.5-26.7)	1.4 (0.4-5.4)	0.548
AST (IU/L)	44 (20-85)	33 (14-156)	0.450
ALT (IU/L)	29 (10-53)	29 (8-73)	0.636
FBG (mg/dL)	97 (62-166)	129 (99-151)	0.079
IRI (μU/mL)	11.1 (3.5-107.3)	8.6 (4.5-14.5)	0.683
TC (mg/dL)	114 (102-177)	196 (87-377)	0.205
TG (mg/dL)	81 (23-114)	125 (80-314)	0.015
FFA (mEq/L)	0.77 (0.25-1.57)	0.53 (0.45-0.61)	0.277
BUN (mg/dL)	17 (5-44)	17 (4-66)	0.925
Cr (mg/dL)	0.79 (0.43-2.09)	0.58 (0.42-1.97)	0.549
Na (mEq/L)	137 (125-143)	137 (126-140)	0.751
K (mEq/L)	4.0 (3.3-4.9)	4.0 (3.3-4.9)	0.411
Cl (mEq/L)	104 (91-108)	103 (94-107)	1.000
Ca (mg/dL)	8.5 (8.2-9.3)	9.3 (8.6-9.8)	0.122
P (mg/dL)	3.3 (2.6-4.6)	3.1 (1.9-4.3)	0.793
PT (%)	60 (32-85)	66 (32-120)	0.284
NH ₃ (μg/dL)	77 (34-174)	91 (48-145)	1.000
BTR	2.98 (2.51-7.26)	5.47 (1.32-8.85)	0.275
History of alcohol intake (non- or light-drinker/drinker/unknown)	8/5/1	7/0/2	0.131
Diabetes mellitus (absent/present)	9/5	3/6	0.214
Hypertension (absent/present)	10/4	6/3	1.000
Esophageal varices (absent/present)	5/9	7/2	0.089
BCAA treatment (absent/present)	7/7	6/3	0.669

Refer to the text in the Patients and Methods section and Table 2 for abbreviations.

Age, height, body weight, body mass index, metabolic parameters, peripheral platelet count, and blood biochemical parameters are expressed as median (range).




Figure 1. Comparison of % resting energy expenditure and respiratory quotient among patients who are categorized as Child-Pugh grade A, B, and C

tended to be higher in patients who had an RQ less than 0.85 than in patients who had an RQ of 0.85 or more (Fig. 2). Patients with "HCV-related" cirrhosis were more common, and patients with autoimmune-related ("others") cirrhosis were less common in the group of RQ<0.85. Child-Pugh grade and %REE were similar in patients who had an RQ less than 0.85 and patients who had an RQ of 0.85 or more.




Figure 2. Comparison of serum triglyceride and free fatty acid concentration between patients who have a respiratory quotient less than 0.85 and patients who have a respiratory quotient of 0.85 or more

Frequency of protein-energy malnutrition in patients with liver cirrhosis

Of the 23 patients with liver cirrhosis, 11 patients (47.8%) had an RQ less than 0.85 and serum ALB less than 3.5 g/dL, suggesting PEM (Table 5). The frequencies of patients with PEM were 25.0% (2 out of 8 patients) in Child-Pugh grade A, 57.1% (4 out of 7 patients) in Child-Pugh grade B, and 62.5% (5 out of 8 patients) in Child-Pugh grade C.

Table 5. Number and frequency of protein-energy malnutrition in patients with liver cirrhosis

	Serum albumin <3.5 g/dL	Serum albumin ≥ 3.5 g/dL
RQ ≥ 0.85	4 (17.4%)	5 (21.7%)
RQ < 0.85	11 (47.8%)	3 (13.0%)

RQ, respiratory quotient.

Discussion

Resting energy expenditure, the amount of calories required by a body for a 24-hour period of inactivity (lying in bed at rest in a comfortable environment), is a marker of metabolic status. To eliminate the effects of age, sex, height, and body weight on REE, the predicted REE is calculated by the Harris-Benedict equations.¹⁷ A %REE (measured REE/predicted REE) of more than 1.1 is usually considered to be a hypermetabolic status.³ For example, %REE is reported to increase in patients with cancer because the competition for nutrients between the tumor and the host can lead to an accelerated starvation state that promotes metabolic disturbances (alterations in carbohydrate, lipid, and protein metabolism) in the host, including hypermetabolism, which leads to decreased energy efficiency.^{18,19} The patients with liver cirrhosis also showed some signs of PEM, but whether increased basal or resting energy expenditure is a constant feature remains controversial.^{1,3,12,20-22} Kato et al.¹ reported that the basal energy expenditure in liver cirrhosis was elevated with decreased oxidation rates of carbohydrate and protein and an increased oxidation rate of fat. They also reported that REE was higher in patients with more advanced disease such as Child-Pugh grades B and C.¹ In the present study, however, the median value of %REE was just 100%, and there was no significant difference in %REE among patients who were categorized as Child-Pugh grade A, B, and C. Moreover, the median value of %REE was highest in Child-Pugh grade A and lowest in grade C. The reason for these discrepancies is unclear. Some of the possible explanations would be heterogenous patients populations and methodologic problems associated with the measurement of energy expenditure because REE could not be accurately predicted by using Harris-Benedict equations.¹⁹ In the cirrhotic patients with peripheral edema and/or ascites, the predicted REE is sometimes over-estimated. In fact, 52.2% of our patients (12 out of 23 patients) had ascites.

The RQ, the ratio of the volume of carbon dioxide produced to the volume of oxygen consumed during respiration, is a useful marker to estimate energy metabolism and

can be used to determine which nutrients are being used as an energy source.¹¹ During aerobic respiration, the respiration of fat gives an RQ of 0.7, the respiration of protein gives an RQ of 0.8, and the respiration of carbohydrate gives an RQ of 1.0. Usually, the RQ ranges from 0.7 to 1.0 and averages around 0.82 in a healthy person. In cases of liver cirrhosis, the RQ is reported to be lower than in healthy subjects.⁷ Enhanced lipid oxidation and reduced glucose oxidation can be responsible for the decrease in RQ. Reduced glucose oxidation is due to the lower production rate of glucose from glycogen, the decrease in peripheral glucose use, and the decrease in hepatic glycogen stores.³ Kato et al.¹ also reported that the basal oxidation rate of fat was increased in patients with liver cirrhosis and therefore, the RQ was significantly lower in patients with liver cirrhosis than in healthy volunteers. In our present study, the median value of RQ was 0.83 and there were no significant differences in RQ among Child-Pugh grade A, B, and C. However, the range of RQ tended to be highest in Child-Pugh grade A and lowest in grade C, although there were not statistically significant.

Tajika et al.³ reported that an RQ of 0.85 was the point at which substrate for thermogenesis turned from carbohydrate dominant (RQ>0.85) to fat dominant (RQ<0.85), and the survival rate was significantly lower in patients with liver cirrhosis with a low RQ (<0.85) than in patients with RQ scores above 0.85. Therefore, we conducted a comparison of clinical features between patients who had an RQ less than 0.85 and patients who had an RQ of 0.85 or more. As a result, Child-Pugh grade and %REE were similar in patients who had an RQ less than 0.85 and patients who had an RQ of 0.85 or more.

It is not surprising that there was a significant difference in serum TC but not TG among patients who were categorized as Child-Pugh grade A, B, and C. However, serum TG was significantly lower in patients who had an RQ less than 0.85 than in patients who had an RQ of 0.85 or more, and FFA tended to be higher in patients who had an RQ less than 0.85 than in patients who had an RQ of 0.85 or more. These results may suggest that serum TG concentration reflects the status of fat metabolism but not liver function, and also, that the increase in FFA in liver cirrhosis might be due to enhanced lipolysis. Plasma FFA oxidation rate has been reported to increase in cirrhosis. This can suppress the syntheses of TG and very low density lipoprotein (VLDL) in liver, and therefore, decreases serum concentration of TG-rich lipoproteins such as VLDL.²³

Albumin synthesis appears to parallel liver function and skeletal muscle protein synthesis is diminished in liver

cirrhosis.⁹ Normal protein nutrition state can be defined as serum ALB concentrations above 3.5 g/dL.³ In the present study, 78.3% of patients were in a state of protein and/or energy malnutrition: 17.4% had protein malnutrition alone (RQ of 0.85 or more and serum ALB of less than 3.5 g/dL), 13.0% had energy malnutrition alone (RQ of less than 0.85 and serum ALB of 3.5 g/dL or more), and 47.8% had PEM (RQ of less than 0.85 and serum ALB of less than 3.5 g/dL). Our data were in line with the previously reported results of Tajika et al.³ that 87% of patients with liver cirrhosis were in a state of either protein or energy malnutrition. Moreover, PEM was more frequently observed at advanced stages of liver cirrhosis such as Child-Pugh grade B (57.1%) and grade C (62.5%) than grade A (25.0%) in our patients, as previously described.^{6,8}

In conclusion, our results revealed that %REE and RQ were not associated with liver function, but the distribution of RQ tended to be highest in Child-Pugh grade A and lowest in grade C, suggesting that the oxidation rate of fat was increased in advanced liver cirrhosis. Overall, 78.3% of patients were in a state of protein and/or energy malnutrition. In our patients, 43.5% (10 out of 23 patients) received oral BCAA treatment, particularly patients with Child-Pugh grade C or an RQ less than 0.85. Oral supplementation with BCAA is reported to be effective not only in treating hepatic encephalopathy but also in improving protein malnutrition.^{1,24} Because the PEM state in liver cirrhosis leads to a poor prognosis, adequate nutritional support is very important.² A longitudinal study in a large population is needed to determine the efficacy of %REE and RQ measurements by indirect calorimetry for adequate nutritional treatment and improvement of patient outcome.

References

1. Kato M, Miwa Y, Tajika M, Hiraoka T, Muto Y, Moriwaki H. Preferential use of branched-chain amino acids as an energy substrate in patients with liver cirrhosis. *Intern Med* 37: 429-434, 1998
2. Miwa Y, Shiraki M, Kato M, et al. Improvement of fuel metabolism by nocturnal energy supplementation in patients with liver cirrhosis. *Hepatol Res* 18: 184-189, 2000
3. Tajika M, Kato M, Mohri H, et al. Prognostic value of energy metabolism in patients with viral liver cirrhosis. *Nutrition* 18: 229-234, 2002
4. Fukushima H, Miwa Y, Ida E, et al. Nocturnal branched-chain amino acid administration improves protein metabolism in patients with liver cirrhosis: comparison with daytime administration. *JPEN* 27: 315-322, 2003
5. Marchesini G, Bianchi G, Merli M, et al. Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. *Gastroenterology* 124: 1792-1801, 2003
6. Muller MJ. Malnutrition and hypermetabolism in patients with liver cirrhosis. *Am J Clin Nutr* 85: 1167-1168, 2007

7. Fan C-L, Wu Y-J, Duan Z-P, Zhang B, Dong P-L, Ding H-G. Resting energy expenditure and glucose, protein and fat oxidation in severe chronic virus hepatitis B patients. *World J Gastroenterol* 14: 4365-6369, 2008
8. Lautz HU, Selberg O, Korber J, Burger M, Muller MJ. Protein-calorie malnutrition in liver cirrhosis. *Clin Invest* 70: 478-486, 1992
9. Tessari P. Protein metabolism in liver cirrhosis: from albumin to muscle myofibrils. *Curr Opin Clin Nutr Metab Care* 6: 79-85, 2003
10. Yamanaka-Okumura H, Nakamura T, Miyake H, et al. Effect of long-term late-evening snack on health-related quality of life in cirrhotic patients. *Hepatol Res* 40: 470-476, 2010
11. Terakura Y, Shiraki M, Nishimura K, Iwasa J, Nagaki M, Moriwaki H. Indirect calorimetry and anthropometry to estimate energy metabolism in patients with liver cirrhosis. *J Nutr Sci Vitaminol* 56: 372-379, 2010
12. Piche T, Schneider SM, Tran A, Benzaken S, Rampal P, Hebuterne X. Resting energy expenditure in chronic hepatitis C. *J Hepatol* 33: 623-627, 2000
13. Kawabe N, Hashimoto S, Harata M, et al. Assessment of nutritional status of patients with hepatitis C virus-related liver cirrhosis. *Hepatol Res* 38: 484-490, 2008
14. Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. *Br J Surg* 60: 646-649, 1973
15. Liver Cancer Study Group of Japan. The general rules for the clinical and pathological study of primary liver cancer. 4th ed. Kanehara & Co., Ltd., Tokyo, 2003.
16. Weir JB. New methods for calculating metabolic rate with special reference to protein metabolism. *J Physiol* 109: 1-12, 1949
17. Harris JA, Benedict FG. A biometric study of human basal metabolism. *Proc Natl Acad Sci USA* 4: 370-373, 1918
18. Esper DH, Harb WA. The cancer cachexia syndrome: a review of metabolic and clinical manifestations. *Nutr Clin Pract* 20: 369-376, 2005
19. Argiles JM, Busquets S, Garcia-Martinez C, Lopez-Soriano FJ. Mediators involved in the cancer anorexia-cachexia syndrome: past, present, and future. *Nutrition* 21: 977-985, 2005
20. Dolz C, Raurich JM, Ibanez J, Obrador A, Marse P, Gaya J. Ascites increases the resting energy expenditure in liver cirrhosis. *Gastroenterology* 100: 738-744, 1991
21. Muller MJ, Boker KHW, Selberg O. Are patients with liver cirrhosis hypermetabolic? *Clin Nutr* 13: 131-144, 1994
22. Greco AV, Mingrone G, Benedetti G, Capristo E, Tataranni PA, Gasbarrini G. Daily energy and substrate metabolism in patients with cirrhosis. *Hepatology* 27: 346-350, 1998
23. Riggio O, Merli M, Cantafora A, et al. Total and individual free fatty acid concentrations in liver cirrhosis. *Metabolism* 33: 646-651, 1984
24. Nakaya Y, Okita K, Suzuki K, et al. BCAA-enriched snack improves nutritional state of cirrhosis. *Nutrition* 23: 113-120, 2007